SARS-CoV-2 coinfection in immunocompromised host leads to the generation of recombinant strain.

Co-infection Plaque assay Recombinant XS SARS-CoV-2 variants Whole genome sequencing

Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 31 10 2022
revised: 21 02 2023
accepted: 07 03 2023
medline: 5 5 2023
pubmed: 17 3 2023
entrez: 16 3 2023
Statut: ppublish

Résumé

Recombination related to coinfection is a huge driving force in determining the virus genetic variability, particularly in conditions of partial immune control, leading to prolonged infection. Here, we characterized a distinctive mutational pattern, highly suggestive of Delta-Omicron double infection, in a lymphoma patient. The specimen was characterized through a combined approach, analyzing the results of deep sequencing in primary sample, viral culture, and plaque assay. Bioinformatic analysis on the sequences deriving from the primary sample supports the hypothesis of a double viral population within the host. Plaque assay on viral culture led to the isolation of a recombinant strain deriving from Delta and Omicron lineages, named XS, which virtually replaced its parent lineages within a single viral propagation. It is impossible to establish whether the recombination event happened within the host or in vitro; however, it is important to monitor co-infections, especially in the exceptional intrahost environment of patients who are immunocompromised, as strong driving forces of viral evolution.

Identifiants

pubmed: 36924839
pii: S1201-9712(23)00088-7
doi: 10.1016/j.ijid.2023.03.014
pmc: PMC10014127
pii:
doi:

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

65-70

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no competing interests to declare.

Auteurs

Silvia Zannoli (S)

Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesestina di Cesena (FC), Italy. Electronic address: silvia.zannoli@auslromagna.it.

Martina Brandolini (M)

Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesestina di Cesena (FC), Italy.

Maria Michela Marino (MM)

Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesestina di Cesena (FC), Italy.

Agnese Denicolò (A)

Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesestina di Cesena (FC), Italy.

Andrea Mancini (A)

Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesestina di Cesena (FC), Italy.

Francesca Taddei (F)

Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesestina di Cesena (FC), Italy.

Valentina Arfilli (V)

Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesestina di Cesena (FC), Italy.

Martina Manera (M)

Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesestina di Cesena (FC), Italy.

Giulia Gatti (G)

Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesestina di Cesena (FC), Italy.

Arianna Battisti (A)

Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesestina di Cesena (FC), Italy.

Laura Grumiro (L)

Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesestina di Cesena (FC), Italy.

Agata Scalcione (A)

Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesestina di Cesena (FC), Italy.

Giorgio Dirani (G)

Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesestina di Cesena (FC), Italy.

Vittorio Sambri (V)

Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesestina di Cesena (FC), Italy; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Pievesestina di Cesena (FC), Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH